New drug combo shows promise for tough breast cancer

NCT ID NCT02158507

Completed Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a combination of two drugs, veliparib and lapatinib, in 20 people with metastatic triple negative breast cancer that had already been treated. The main goal was to see how safe the combination is and how many patients respond. All participants received the drugs; there was no placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: veliparib and lapatinib
What this could lead to: If this drug combination works, it could offer a new treatment option for people with metastatic triple negative breast cancer who have few other choices.
What could go wrong: This is a very small pilot study with only 20 people, so results may not apply broadly. The drugs can cause serious side effects, and veliparib is not yet FDA-approved.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC TRIPLE-NEGATIVE BREAST CANCER

Contacts and locations

Locations

University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.